Detection and quantification of cyclosporine in body fluids using an interleukin-2 receptor-gene assay

Journal of Immunological Methods

Volumn 201, Issue 1, 1997, Pages 125-135

  Wenner, Peter R ^a   Di Padova, Franco ^a   Keown, Paul A ^b  

^a Preclinical Research   (Switzerland)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

immunosuppressive; reporter gene assay; therapeutic monitoring

Indexed keywords

ASCOMYCIN; CYCLOSPORIN; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NORMAL HUMAN; PRIORITY JOURNAL; REPORTER GENE;

AMINO ACID ISOMERASES; BIOLOGICAL ASSAY; CARRIER PROTEINS; CELL LINE; CYCLOSPORINE; GENE EXPRESSION; GENES, REPORTER; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; PEPTIDYLPROLYL ISOMERASE; PROMOTER REGIONS (GENETICS); PROTEIN BINDING;

ANIMALIA;

EID: 0031033060     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(96)00219-0     Document Type: Article

References (32)

1. Annesley, T.M., Giacherio, D.A. and Feldkamp, C.S. (1986) The concentratio-related distribution of cyclosporine in blood. J. Clin. Immunoassay 9, 53.
2. 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin. Chem. 34, 257.
3. Baumann, G., Geisse, S. and Sullivan, M. (1991) Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. New Biol. 3, 270.
4. Baumann, G., Andersen, E., Quesniaux, V. and Eberle, M.K. (1992) Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation - a comparative analysis in vitro. Transplant. Proc. 24, 43.
5. Bolton, C. (1992) The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). Agents Actions 35, 79.
6. Borel, J.F., Feurer, C., Gubler, H.U. and Stähelin, H. (1976) Biological effect of cyclosporin A: a new antilymphocytic agent. Agents Actions 6, 468.
7. Consensus Document: (1990) Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant. Proc. 22, 1357.
8. Eberle, M.K. and Nuninger, F. (1992) Synthesis of the main metabolite (OL-17) of cyclosporin A. J. Org. Chem. 57, 2689.
9. Feutren, G. (1992) The optimal use of cyclosporin A in autoimmune diseases [erratum appeared in J. Autoimmun. (1992) 5, 545]. J. Autoimmun. 5 (suppl. A), 183.
10. Freed, B.M., Stevens, C., Brooks, C., Cramer, S., Lempert, N. and Rosano, T.G. (1991) Assessment of the biological activity of cyclosporine metabolites using the human Jurkat cell line. Transplant. Proc. 23, 980.
11. Holt, D.W. and Johnston, A. (1992) Cyclosporin monitoring: its role in autoimmune indications. J. Autoimmun. 5, 177.
12. Holt, D.W. and Johnston, A. (1994) Pharmacokinetics and monitoring of cyclosporin A. In: A.W. Thomson and T.E. Starzl (Eds.), Immunosuppressive Drugs-Developments in Anti-Rejection Therapy. Edward Arnold, London, p. 37.
13. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., Kohsaka, M., Aoki, M. and Imanaka, H. (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, physico-chemical characteristics. J. Antibiot. 40, 1249.
14. Kovarik, J.M., Mueller, E.A., van Bree, J.B., Tetzloff, W. and Kutz, K. (1994) Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83, 444.
15. Kroencke, M., Leonard, W.J., Depper, M.J., Arya, S.K., Wong-Staal, F., Gallo, R.C., Waldmann, T.A. and Greene, T.C. (1984) Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl. Acad. Sci. USA 81, 5214.
16. Mattila, P.S., Ullman, K.S., Fiering, S., Emmel, E.A., McCutcheon, M., Crabtree, G.R. and Herzenberg, L.A. (1990) The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J. 9, 4425.
17. Mueller, E.A., Kovarik, J.M., van Bree, J.B., Tetzloff, W., Grevel, J. and Kutz, K. (1994) Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11, 301.
18. Napoli, K.L. and Kahan, B.D. (1991) Considerations for monitoring cyclosporine in transplant recipients. Clin. Lab. Med. 11, 671.
19. Quesniaux, V.F.J., Schreier, M.H., Wenger, R.M., Hiestand, P.C., Harding, M.W. and van Regenmortel, M.H.V. (1987) Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 17, 1359.
20. Quesniaux, V.F., Schmitter, D., Schreier, M.H. and Van Regenmortel, M.H. (1990) Monoclonal antibodies to cyclosporin are representative of the major antibody populations present in antisera of immunized mice. Mol. Immunol. 27, 227.
21. Russell, R.L., Donnelly, J.G., Palaszynski, E.W., Chan, M.M. and Soldin, S.J. (1991) A preliminary study to evaluate an in vitro assay for determining patient whole blood immunosuppressive cyclosporine A and metabolite activity: comparison with cytosolic binding assays using cyclophilin or a 50-kilodalton binding protein, and the Abbott TDx cyclosporine A parent, and parent and metabolites assays. Ther. Drug Monit. 13, 32.
22. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
23. Schneider, H., Charara, N., Schmitz, R., Wehrli, S., Mikol, V., Zurini, M.G., Quesniaux, V.F. and Movva, N.R. (1994) Human cyclophilin C: primary structure, tissue distribution, and determination of binding specificity for cyclosporins. Biochemistry 33, 8218.
24. Schreiber, S.L. and Crabtree, G.R. (1992) The mechanism of action of cyclosporin A and FK506. Immunol. Today 13, 136.
25. Schreier, M.H. and Tees, R. (1981) Long-Term Culture and Cloning of Specific Helper T Cells. In: I. Lefkovits and B. Pernis (Eds.), Immunological Methods, Vol. 2. Academic Press, New York, p. 263.
26. Sehgal, S.N. (1995) Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther. Drug Monit. 17, 660.
27. Shaw, L.M. (1989) Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. Clin. Chem. 35, 1299.
28. Siekierka, J.J. and Sigal, N.H. (1992) FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr. Opin. Immunol. 4, 548.
29. Spiers, E.M. and Beck, J.S. (1991) Inter- and intra-subject variation of the suppression of mitogen-induced proliferation of human lymphocytes by cyclosporin-A: reduction of response with delayed addition may be relevant to timing of therapy. Int. J. Immunopharmacol. 13, 245.
30. Vine, W. and Bowers, L.D. (1987) Cyclosporine: structure, pharmacokinetics and therapeutic drug monitoring [Review]. Crit. Rev. Clin. Lab. Sci. 25, 275.
31. Wenger, R.M., Martin, K., Timbers, C. and Tromelin, A. (1992) Structure of cyclosporine and its metabolites: total synthesis of cyclosporine metabolites formed by oxidation at positions 4 and 9 of cyclosporine. Preparation of leucine-4-cyclosporine, (γ-hydroxy)-N-methyl-leucine-9-cyclosporine and leucine-4-(γ-hydroxy)-N-methyl-leucine-9-cyclosporine. Chimia 46, 314.
32. Zenke, G., Baumann, G., Wenger, R., Hiestand, P., Quesniaux, V., Andersen, E. and Schreier, M.H. (1993) Molecular mechanisms of immunosuppression by cyclosporins. Ann. N.Y. Acad. Sci. 685, 330.